Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 1997

View Archived Issues

Genome Therapeutics: Q4 and FY 1997 highlights

Diatide: Q3 1997 highlights

Connetics: Q3 1997 highlights

Sepracor: Q3 1997 highlights

Genzyme General: Q3 1997 highlights

Roussel Morishita reports antiulcer agents with a novel mechanism of action

BE-52440A and BE-52440B: novel antitumor antibiotics reported in patent literature

Vaxcel: Q3 1997 highlights

OP-1 effective in preclinical model of stroke

New compound isolated from the African tarantula by Neurex

Gene for estrogen receptor-postive cancers available for licensing

ID Vaccine and the NIAID collaborate on GAS vaccine

Angiogenesis-inhibitory peptides available for licensing from NIH

Antiprogestational agents available from the NIH

rPAF-AH proceeds to phase II for asthma

IntraBiotics codevelops IB-367 with Pharmacia & Upjohn

CoCensys licenses small molecules with anticonvulsant and potential analgesic effects

Phase Ia trial of ADCI successfully completed

CNS-5161 clinical update

Johnson & Johnson and Japan Tobacco sign licensing agreement

HMR discloses azasteroids for estrogen/androgen-mediated disorders

Antimicrobial GE-2270 derivatives from Biosearch

Lexipafant as adjunct for severe acute pancreatitis

Temozolomide: phase II efficacy and tolerability data in patients with high-grade glioma

Takeda discovers new Taxol-like compound

First oral, tumor-activated anticancer drug filed by Roche

New immunomodulators for treating rheumatoid arthritis

New neurotransmitter implicated in hunger and satiety

Mechanism of glucocorticoid antiinflammatory effects elucidated

New tumor contrast agents disclosed

Recordati's lercanidipine launched in The Netherlands

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...